Combinatorial Effect of Temozolomide and Naringenin in Human Glioblastoma Multiforme Cell Lines

Gautam, Megha; Gabrani, Reema

doi:10.1080/01635581.2021.1952438

Cited by 10 publications

(2 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other clinically relevant phenomena such as reported phytochemical inhibition of acquired drug resistance in cancer cell lines can be investigated in a more functional context using MPS tumor models. [ 76 ] Taken together, the MPS reported in this study and their future iterations can serve as valuable tools to accelerate the discovery and translation of phytochemicals for the prevention and treatment of cancer and other diseases.…”

Section: Discussionmentioning

confidence: 97%

Xenohormetic Phytochemicals Inhibit Neovascularization in Microphysiological Models of Vasculogenesis and Tumor Angiogenesis

Kpeli,

Conrad,

Bralower

et al. 2024

Advanced Biology

View full text Add to dashboard Cite

Xenohormesis proposes that phytochemicals produced to combat stressors in the host plant exert biochemical effects in animal cells lacking cognate receptors. Xenohormetic phytochemicals such as flavonoids and phytoalexins modulate a range of human cell signaling mechanisms but functional correlations with human pathophysiology are lacking. Here, potent inhibitory effects of grapefruit‐derived Naringenin (Nar) and soybean‐derived Glyceollins (Gly) in human microphysiological models of bulk tissue vasculogenesis and tumor angiogenesis are reported. Despite this interference of vascular morphogenesis, Nar and Gly are not cytotoxic to endothelial cells and do not prevent cell cycle entry. The anti‐vasculogenic effects of Glyceollin are significantly more potent in sex‐matched female (XX) models. Nar and Gly do not decrease viability or expression of proangiogenic genes in triple negative breast cancer (TNBC) cell spheroids, suggesting that inhibition of sprouting angiogenesis by Nar and Gly in a MPS model of the (TNBC) microenvironment are mediated via direct effects in endothelial cells. The study supports further research of Naringenin and Glyceollin as health‐promoting agents with special attention to mechanisms of action in vascular endothelial cells and the role of biological sex, which can improve the understanding of dietary nutrition and the pharmacology of phytochemical preparations.

show abstract

Section: Discussionmentioning

confidence: 97%

Xenohormetic Phytochemicals Inhibit Neovascularization in Microphysiological Models of Vasculogenesis and Tumor Angiogenesis

Kpeli,

Conrad,

Bralower

et al. 2024

Advanced Biology

View full text Add to dashboard Cite

show abstract

“…Recently, Gautam et al found synergism between naringenin, a flavonoid found in grapefruit, and TMZ in restricting growth and enhancing cytotoxic effects against U87MG and LN229 cell lines [21]. Additionally, the study demonstrated a significant decrease in both single-cell colony formation and cell migration.…”

Section: Enhancing Temozolomide Response With Phytochemicalsmentioning

confidence: 91%

New Avenues and Major Achievements in Phytocompounds Research for Glioblastoma Therapy

Majchrzak-Celińska,

Studzińska-Sroka

2024

Molecules

View full text Add to dashboard Cite

Phytocompounds have been evaluated for their anti-glioblastoma actions for decades, with promising results from preclinical studies but only limited translation into clinics. Indeed, by targeting multiple signaling pathways deregulated in cancer, they often show high efficacy in the in vitro studies, but their poor bioavailability, low tumor accumulation, and rapid clearance compromise their efficacy in vivo. Here, we present the new avenues in phytocompound research for the improvement of glioblastoma therapy, including the ways to enhance the response to temozolomide using phytochemicals, the current focus on phytocompound-based immunotherapy, or the use of phytocompounds as photosensitizers in photodynamic therapy. Moreover, we present new, intensively evaluated approaches, such as chemical modifications of phytochemicals or encapsulation into numerous types of nanoformulations, to improve their bioavailability and delivery to the brain. Finally, we present the clinical trials evaluating the role of phytocompounds or phytocompound-derived drugs in glioblastoma therapy and the less studied phytocompounds or plant extracts that have only recently been found to possess promising anti-glioblastoma properties. Overall, recent advancements in phytocompound research are encouraging; however, only with more 3D glioblastoma models, in vivo studies, and clinical trials it is possible to upgrade the role of phytocompounds in glioblastoma treatment to a satisfactory level.

show abstract

Future Perspectives of Phytochemicals in Cancer Therapy

Bağca

Avci²

2022

Interdisciplinary Cancer Research

View full text Add to dashboard Cite

Combinatorial Effect of Temozolomide and Naringenin in Human Glioblastoma Multiforme Cell Lines

Cited by 10 publications

References 42 publications

Xenohormetic Phytochemicals Inhibit Neovascularization in Microphysiological Models of Vasculogenesis and Tumor Angiogenesis

Xenohormetic Phytochemicals Inhibit Neovascularization in Microphysiological Models of Vasculogenesis and Tumor Angiogenesis

New Avenues and Major Achievements in Phytocompounds Research for Glioblastoma Therapy

Future Perspectives of Phytochemicals in Cancer Therapy

Contact Info

Product

Resources

About